drugset / Trial / NCT00039273
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
Phase 2
Completed
44 enrolled
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory metastatic colorectal cancer.
Timeline
- Start
- 2002-07
- Primary completion
- 2003-05
- Completion
- —
Publications
- Results Meropol NJ, Berlin J, Hecht JR, et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1026, 256, 2003.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | — | Intravenous |